Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hidekatsu Yanai

Showing results (51-60 of 127) with videos related to

Pageof 13
Sort By:
International Journal of Molecular Sciences|March 28, 2026
Molecular Mechanisms and Clinical Evidence Supporting the Four Pillars of Therapy in Diabetic Kidney Disease: Emerging Therapeutic PerspectivesHidekatsu Yanai, Hiroki Adachi, Mariko Hakoshima, et al.
Endocrinology|March 18, 2003
Conservation of the hydroxysteroid sulfotransferase SULT2B1 gene structure in the mouse: pre- and postnatal expression, kinetic analysis of isoforms, and comparison with prototypical SULT2A1Chikara Shimizu, Hirotoshi Fuda, Hidekatsu Yanai, et al.
BMJ Open|January 18, 2015
The association between daily physical activity and plasma B-type natriuretic peptide in patients with glucose intolerance: a cross-sectional studyHidetaka Hamasaki, Hidekatsu Yanai, Masafumi Kakei, et al.
Journal of Atherosclerosis and Thrombosis|December 29, 2006
The possible contribution of a general glycosphingolipid transporter, GM2 activator protein, to atherosclerosisHidekatsu Yanai, Hiroshi Yoshida, Yoshiharu Tomono, et al.
Endocrine Journal|December 7, 2025
The association between thyroid hormone levels and psychiatric symptoms in patients with mania or depressionMariko Hakoshima, Sarina Tanida, Hisayuki Katsuyama, et al.
Cells|March 13, 2024
A Possible Therapeutic Application of the Selective Inhibitor of Urate Transporter 1, Dotinurad, for Metabolic Syndrome, Chronic Kidney Disease, and Cardiovascular DiseaseHidekatsu Yanai, Hiroki Adachi, Mariko Hakoshima, et al.
Journal of Clinical Medicine Research|February 9, 2023
Clinical, Hematological, Biochemical and Radiological Characteristics for Patients With Splenic Infarction: Case Series With Literature ReviewMariko Hakoshima, Kazuya Kitakaze, Hiroki Adachi, et al.
Biomolecules|August 29, 2024
The Significance of Endothelial Dysfunction in Long COVID-19 for the Possible Future Pandemic of Chronic Kidney Disease and Cardiovascular DiseaseHidekatsu Yanai, Hiroki Adachi, Mariko Hakoshima, et al.
World Journal of Diabetes|May 4, 2011
Dipeptidyl peptidase-4 inhibitor for steroid-induced diabetesHidekatsu Yanai, Yoshinori Masui, Reo Yoshikawa, et al.
Journal of Clinical Medicine Research|April 18, 2015
Effects of 6-month sitagliptin treatment on metabolic parameters in diabetic patients taking oral glucocorticoids: a retrospective cohort studyHisayuki Katsuyama, Akahito Sako, Hiroki Adachi, et al.
Pageof 13

Showing results (51-60 of 127) with videos related to

Sort By:
Pageof 13
International Journal of Molecular Sciences|March 28, 2026
Molecular Mechanisms and Clinical Evidence Supporting the Four Pillars of Therapy in Diabetic Kidney Disease: Emerging Therapeutic PerspectivesHidekatsu Yanai, Hiroki Adachi, Mariko Hakoshima, et al.
Endocrinology|March 18, 2003
Conservation of the hydroxysteroid sulfotransferase SULT2B1 gene structure in the mouse: pre- and postnatal expression, kinetic analysis of isoforms, and comparison with prototypical SULT2A1Chikara Shimizu, Hirotoshi Fuda, Hidekatsu Yanai, et al.
BMJ Open|January 18, 2015
The association between daily physical activity and plasma B-type natriuretic peptide in patients with glucose intolerance: a cross-sectional studyHidetaka Hamasaki, Hidekatsu Yanai, Masafumi Kakei, et al.
Journal of Atherosclerosis and Thrombosis|December 29, 2006
The possible contribution of a general glycosphingolipid transporter, GM2 activator protein, to atherosclerosisHidekatsu Yanai, Hiroshi Yoshida, Yoshiharu Tomono, et al.
Endocrine Journal|December 7, 2025
The association between thyroid hormone levels and psychiatric symptoms in patients with mania or depressionMariko Hakoshima, Sarina Tanida, Hisayuki Katsuyama, et al.
Cells|March 13, 2024
A Possible Therapeutic Application of the Selective Inhibitor of Urate Transporter 1, Dotinurad, for Metabolic Syndrome, Chronic Kidney Disease, and Cardiovascular DiseaseHidekatsu Yanai, Hiroki Adachi, Mariko Hakoshima, et al.
Journal of Clinical Medicine Research|February 9, 2023
Clinical, Hematological, Biochemical and Radiological Characteristics for Patients With Splenic Infarction: Case Series With Literature ReviewMariko Hakoshima, Kazuya Kitakaze, Hiroki Adachi, et al.
Biomolecules|August 29, 2024
The Significance of Endothelial Dysfunction in Long COVID-19 for the Possible Future Pandemic of Chronic Kidney Disease and Cardiovascular DiseaseHidekatsu Yanai, Hiroki Adachi, Mariko Hakoshima, et al.
World Journal of Diabetes|May 4, 2011
Dipeptidyl peptidase-4 inhibitor for steroid-induced diabetesHidekatsu Yanai, Yoshinori Masui, Reo Yoshikawa, et al.
Journal of Clinical Medicine Research|April 18, 2015
Effects of 6-month sitagliptin treatment on metabolic parameters in diabetic patients taking oral glucocorticoids: a retrospective cohort studyHisayuki Katsuyama, Akahito Sako, Hiroki Adachi, et al.
Pageof 13